Neuropathy As an Adverse Effect of Chemotherapy Diminished After Administration of Dietary Supplement with Iron Citrate

Neuropathy As an Adverse Effect of Chemotherapy Diminished After Administration of Dietary Supplement with Iron Citrate – Case Study

Published:2024-07-02 Issue:3 Volume:3 Page:
ISSN:2956-672X
Container-title:Futurity Medicine
language:
Short-container-title:FM

Author:

Kusnir Patrik^ORCID,Baig Shahbaz^ORCID

Abstract

Aims: This research examined how adding iron citrate (Synthesit) affected chemotherapy-induced nerve damage in a patient diagnosed with primary fallopian tube cancer. Methodology: A 51-year-old Lithuanian woman received adjuvant chemotherapy and iron citrate. The blood indices and inflammation markers were monitored. Results: The patient showed macrocytic normochromic anemia, fluctuating platelet parameters, and varied procalcitonin levels, suggesting Synthesit influences immune function and hematologic parameters during chemotherapy. Scientific Novelty: This study distinctively investigated the influence of iron citrate on changes in hematologic and immune parameters during chemotherapy. Conclusion: Synthesit may affect the blood counts, red blood cell production, and immune markers, aiding in chemotherapy-induced neuropathy management.

Publisher

Futurity Research Publishing

Reference28 articles.

1. Thanasa E, Stamouli D, Gerokostas EE, Balafa K, Koutalia N, Thanasas I. Primary Fallopian Tube Carcinoma: An Extremely Rare Gynecological Cancer Misdiagnosed Intraoperatively as Benign Ovarian Neoplasm: A Case Report. Clin Pract. 2022;12:253. Available from: https://doi.org/10.3390/CLINPRACT12030030

2. Horng HC, Teng SW, Huang BS, Sun HD, Yen MS, Wang PH, et al. Primary fallopian tube cancer: Domestic data and up-to-date review. Taiwan J Obstet Gynecol. 2014;53:287–92. Available from: https://doi.org/10.1016/J.TJOG.2014.07.003

3. Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynecol Obstet. 2021;155:61–85. Available from: https://doi.org/10.1002/IJGO.13878

4. Stasenko M, Fillipova O, Tew WP. Fallopian Tube Carcinoma. J Oncol Pract. 2019;15:375–82. Available from: https://doi.org/10.1200/JOP.18.00662

5. Li S, Yu M, Bai W, Shi J, Di W. Long-term follow-up of 46 cases of primary fallopian tube carcinoma: a single institute study. Ann Palliat Med. 2021;10:9122135–9135. Available from: https://doi.org/10.21037/APM-21-2083